Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma: primary endpoint results, effect estimate with confidence…
- S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00088972).
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.: Complete Statistical AnalysisIndependent statistical analysis of S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction: Complete Statistical AnalysisIndependent statistical analysis of S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction: primary endpoint results, effect estimate with confidence…
- S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate…
- S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo: Complete Statistical AnalysisIndependent statistical analysis of S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval,…
- S0802 – Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…
- S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib: primary endpoint results, effect estimate with…
- S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- S2SIndependent statistical analysis of Screen to Save: A Colorectal Cancer Educational Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03907579).
- S8PKIndependent statistical analysis of Safety and Performance of the Steroid-Releasing S8 Sinus Implant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01894503).
- S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma: Complete Statistical AnalysisIndependent statistical analysis of S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003590).
- SAABIndependent statistical analysis of Corticosteroid Pulse After Ablation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00807586).
- SABRseqIndependent statistical analysis of Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- SACARIndependent statistical analysis of Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study: Complete Statistical AnalysisIndependent statistical analysis of Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study: primary endpoint…
- Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence: Complete Statistical AnalysisIndependent statistical analysis of Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SACRPIndependent statistical analysis of Study of Anaesthesia Costs and Recovery Profiles: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02920749).
- SAD-PDIndependent statistical analysis of Study of Antidepressants in Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00086190).
- SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects: Complete Statistical AnalysisIndependent statistical analysis of SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SADHART-CHFIndependent statistical analysis of Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SAFEIndependent statistical analysis of Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH): primary endpoint results, effect estimate with confidence interval,…
- SAFEIndependent statistical analysis of Safe Administration of Flu Vaccine to Egg Allergic Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01264601).
- SAFEIndependent statistical analysis of Safety, Acceptability, and Feasibility of Enterade®: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03782272).
- Safe and Healthy Schools: Complete Statistical AnalysisIndependent statistical analysis of Safe and Healthy Schools: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05105789).
- SAFERIndependent statistical analysis of Brief Interventions in the Emergency Department for Alcohol and HIV/Sexual Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SAFERIndependent statistical analysis of Sleep Apnea and Fetal Growth Restriction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04084990).
- Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA: Complete Statistical AnalysisIndependent statistical analysis of Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia: Complete Statistical AnalysisIndependent statistical analysis of Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old: Complete Statistical AnalysisIndependent statistical analysis of Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS: Complete Statistical AnalysisIndependent statistical analysis of Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety & Immunogenicity of GlaxoSmithKline Biologicals’ Herpes Zoster Vaccine 1437173A: Complete Statistical AnalysisIndependent statistical analysis of Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00920218).
- Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants: Complete Statistical AnalysisIndependent statistical analysis of Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule: Complete Statistical AnalysisIndependent statistical analysis of Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection: Complete Statistical AnalysisIndependent statistical analysis of Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety & Tolerability Study That Compares Restylane to Restylane With Lidocaine While Correcting Wrinkles in the Nasolabial Folds: Complete Statistical AnalysisIndependent statistical analysis of Safety & Tolerability Study That Compares Restylane to Restylane With Lidocaine While Correcting Wrinkles in the Nasolabial Folds: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Acceptability Study of a Non-Hormonal Ring: Complete Statistical AnalysisIndependent statistical analysis of Safety and Acceptability Study of a Non-Hormonal Ring: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03598088).
- Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel: Complete Statistical AnalysisIndependent statistical analysis of Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.: Complete Statistical AnalysisIndependent statistical analysis of Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05243862).
- Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials: Complete Statistical AnalysisIndependent statistical analysis of Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning…